ASH 2023: Exploring Therapeutic Advancements for Chronic Lymphocytic Leukemia - Episode 12

Emerging Data Surrounding Mechanisms of Resistance to Non-Covalent BTKis

, , , , ,

The expert panel discusses recent data regarding the mechanisms of resistance to non-covalent BTK inhibitors in CLL.

EP. 1: Current Front-Line Treatment Options for CLL in 2023
EP. 2: Exploring BTKi Monotherapy in CLL: Long-Term Updates from ELEVATE-TN and SEQUOIA
EP. 3: Strategies for Managing Treatment-Naïve CLL with High-Risk Features
EP. 4: Impact of Off-Target AEs and Treatment Resistance on Evolving 1L Therapy Strategies for CLL
EP. 5: Exploring the Role of BTKi-Based Combination Therapies for Front-line Management of CLL
EP. 6: Treatment Sequencing Strategies for R/R CLL: Impact of Prior 1L Therapy
EP. 7: Navigating BTKi Therapy in R/R CLL: Updates from ELEVATE-RR and ALPINE
EP. 8: Expert Perspectives on Navigating Treatment Selection with BTKis in CLL
EP. 9: Expert Insights into Navigating Cardiovascular Risks with BTKi Therapy
EP. 10: Treatment Resistance with Covalent BTKis: Translating Data into Clinical Practice
EP. 11: Role of Non-Covalent BTKis in R/R CLL: Updates from Ongoing BRUIN and Bellwave Trials
Now Viewing
EP. 12: Emerging Data Surrounding Mechanisms of Resistance to Non-Covalent BTKis
EP. 13: Expert Insights into Investigation Therapies for CLL
EP. 14: Future Perspectives on the Treatment Landscape for CLL

Related Content:

ASH 2023: Exploring Therapeutic Advancements for Chronic Lymphocytic LeukemiaUCI Health Chao Family Comprehensive Cancer CenterCleveland ClinicAtrium Health Levine CancerMoffitt Cancer CenterRutgers Cancer InstituteChronic Lymphocytic LeukemiaOncLive Peer Exchange®
Sonrotoclax Plus Zanubrutinib Is Safe, Efficacious in Relapsed/Refractory CLL/SLL
Acalabrutinib and Zanubrutinib Both Best Ibrutinib in Real-World Safety and Efficacy CLL/SLL Outcomes
Lower Tumor Burden Associated With Improved ORR With Liso-Cel in R/R CLL/SLL